These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32735518)

  • 1. Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment.
    Kaur M; Nagpal M; Singh M
    Curr Drug Targets; 2020; 21(16):1640-1651. PubMed ID: 32735518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.
    Yang P; Lv S; Wang Y; Peng Y; Ye Z; Xia Z; Ding G; Cao X; Crane JL
    Bone; 2018 Sep; 114():1-13. PubMed ID: 29800693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer therapies for osteoporosis.
    Palaniswamy C; Selvaraj DR; Rao V; Patel U
    Am J Ther; 2010; 17(2):197-200. PubMed ID: 20305400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoblast as a target of anti-osteoporotic treatment.
    Corrado A; Sanpaolo ER; Di Bello S; Cantatore FP
    Postgrad Med; 2017 Nov; 129(8):858-865. PubMed ID: 28770650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model.
    Zhu S; Häussling V; Aspera-Werz RH; Chen T; Braun B; Weng W; Histing T; Nussler AK
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease.
    Hung KC; Chang JF; Hsu YH; Hsieh CY; Wu MS; Wu MY; Chiu IJ; Syu RS; Wang TM; Wu CC; Hung LY; Zheng CM; Lu KC
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolactin A protects against LPS-induced bone loss by regulation of bone remodeling.
    Sapkota M; Gao M; Li L; Yang M; Shrestha SK; Choi H; Soh Y
    Eur J Pharmacol; 2020 Sep; 883():173305. PubMed ID: 32673673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-539 promotes osteoblast proliferation and differentiation and osteoclast apoptosis through the AXNA-dependent Wnt signaling pathway in osteoporotic rats.
    Zhu XB; Lin WJ; Lv C; Wang L; Huang ZX; Yang SW; Chen X
    J Cell Biochem; 2018 Nov; 119(10):8346-8358. PubMed ID: 29893431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model.
    Yu T; Witten PE; Huysseune A; Buettner A; To TT; Winkler C
    Dis Model Mech; 2016 Feb; 9(2):155-63. PubMed ID: 26704995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu maxim.
    Xue L; Jiang Y; Han T; Zhang N; Qin L; Xin H; Zhang Q
    J Ethnopharmacol; 2016 Nov; 192():370-381. PubMed ID: 27422162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin Induces Bone Formation by Increasing Expression of Wnt10b in Osteoclasts in Ovariectomy-Induced Osteoporotic Rats.
    Hsiao CY; Chen TH; Chu TH; Ting YN; Tsai PJ; Shyu JF
    Front Endocrinol (Lausanne); 2020; 11():613. PubMed ID: 33013696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis.
    Whitfield JF; Morley P; Willick GE
    Treat Endocrinol; 2002; 1(3):175-90. PubMed ID: 15799210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?].
    Neumann E
    Z Rheumatol; 2006 Sep; 65(5):400, 402-6. PubMed ID: 16924451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Osteoblast and Osteoclast In Vitro Co-Culture Models and Their Translation for Preclinical Drug Testing Applications.
    Sieberath A; Della Bella E; Ferreira AM; Gentile P; Eglin D; Dalgarno K
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of suppressing osteoclast formation versus function.
    Teitelbaum SL
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii61-ii63. PubMed ID: 27856662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblast-osteoclast interactions.
    Chen X; Wang Z; Duan N; Zhu G; Schwarz EM; Xie C
    Connect Tissue Res; 2018 Mar; 59(2):99-107. PubMed ID: 28324674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tetracyclines on bones: an ambiguous question needs to be clarified.
    Cheng W; Yue Y; Fan W; Hu Y; Wang X; Pan X; Zhou X; Qin L; Zhang P
    Pharmazie; 2012 May; 67(5):457-9. PubMed ID: 22764582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of the Thyroid Hormone Transporter Mct8 in Osteoblast and Osteoclast Progenitors Increases Trabecular Bone in Male Mice.
    Lademann F; Tsourdi E; Rijntjes E; Köhrle J; Hofbauer LC; Heuer H; Rauner M
    Thyroid; 2020 Feb; 30(2):329-342. PubMed ID: 31910109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.